fenofibrate nanoparticle formulation / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 59 Diseases   9 Trials   9 Trials   134 News 


12»
  • ||||||||||  micronized fenofibrate / Generic mfg., fenofibrate / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) -  Sep 21, 2024   
    P1,  N=24, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: May 2025 --> Nov 2026 | Initiation date: Aug 2024 --> Nov 2024 | Trial primary completion date: Jan 2025 --> Jun 2026
  • ||||||||||  fenofibrate / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Fenofibrate Role in Breast Cancer Patients (clinicaltrials.gov) -  Aug 9, 2024   
    P=N/A,  N=50, Completed, 
    Trial completion date: May 2025 --> Nov 2026 | Initiation date: Aug 2024 --> Nov 2024 | Trial primary completion date: Jan 2025 --> Jun 2026 Recruiting --> Completed | Trial completion date: Feb 2024 --> Aug 2024 | Trial primary completion date: Jan 2024 --> Aug 2024
  • ||||||||||  fenofibrate nanoparticle formulation / Generic mfg.
    Journal:  Tailored Sugar-Mediated Porous Particle Structures for Improved Dispersion of Drug Nanoparticles in Spray-Freeze-Drying. (Pubmed Central) -  Jul 3, 2024   
    We fabricated porous particles incorporating sugars (mannitol, sucrose, or dextran) and fenofibrate nanoparticles (FNPs) by using spray-freeze-drying (SFD)...Dextran formed a highly porous network irrespective of the presence of FNPs, whereas mannitol tended to alter the particle attributes upon FNP inclusion. In conclusion, SFD particles derived from dextran and mannitol might help to increase FNP dispersibility by increasing the formation of porous architectures.
  • ||||||||||  CARE OF PATIENTS WITH VITAMIN D DEFICIENCY AND MYASTHENIA GRAVIS () -  Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_862;    
    Initiation date: Feb 2024 --> Aug 2024 The Endocrine nurse plays a crucial role in the multidisciplinary team, and should have good understanding the complexity of this neuromuscular disorder and bone health so as to provide best care for the patient to improve patient's quality of life.
  • ||||||||||  fenofibrate nanoparticle formulation / Generic mfg.
    Journal:  Insight into the mechanism behind oral bioavailability-enhancement by nanosuspensions through combined dissolution/permeation studies. (Pubmed Central) -  Mar 28, 2023   
    Permeation rates were found significantly increased for both nanosuspensions when compared to the raw APIs, indicating a direct implication that formulation strategies are needed, be it stabilization of supersaturation by precipitation inhibition and/or dissolution rate enhancement. This study indicates that in vitro dissolution/permeation studies can be employed to better understand the oral absorption enhancement of nanocrystal formulations.
  • ||||||||||  fenofibrate / Generic mfg.
    Trial completion date, Trial primary completion date:  Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate (clinicaltrials.gov) -  Oct 19, 2022   
    P=N/A,  N=40, Recruiting, 
    Therefore, ROS-sensitive FNB delivery formulations FNB-NP enhance the preventive effects of FNB against NAFLD and could be further studied as a promising drug for the treatment of NAFLD in clinic. Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Apr 2022 --> Dec 2023
  • ||||||||||  micronized fenofibrate / Generic mfg., fenofibrate / Generic mfg.
    A Randomized Trial of Lipid Metabolism Modulation With Fenofibrate for Acute Coronavirus Disease 2019 (Main Event III) -  Oct 5, 2022 - Abstract #AHA2022AHA_7880;    
    P2
    We randomly assigned 701 participants with COVID-19 within 14 days of symptom onset to 145 mg of fenofibrate (nanocrystal formulation with dose adjustment for renal function or dose-equivalent preparations of micronized fenofibrate or fenofibric acid) vs. placebo for 10 days, in a double-blinded fashion. Among patients with COVID-19, fenofibrate has no significant effect on various clinically relevant outcomes.
  • ||||||||||  Journal:  Lipid-lowering drugs. (Pubmed Central) -  Sep 20, 2022   
    Among patients with COVID-19, fenofibrate has no significant effect on various clinically relevant outcomes. No abstract available
  • ||||||||||  fenofibrate nanoparticle formulation / Generic mfg.
    Trial completion date, Trial primary completion date:  FENOC: Fenofibrate for Patients With COVID-19 Requiring Hospitalization (clinicaltrials.gov) -  Mar 10, 2022   
    P3,  N=55, Recruiting, 
    In conclusion, PVA-stabilized FE/RMβCD-loaded EuNP eye drop suspensions were successfully developed, warranting further in vivo testing. Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Apr 2021 --> Mar 2022
  • ||||||||||  fenofibrate nanoparticle formulation / Generic mfg., fenofibrate / Generic mfg.
    Preclinical, Journal:  Fenofibrate Nano-Eyedrops Ameliorate Retinal Blood Flow Dysregulation and Neurovascular Coupling in Type 2 Diabetic Mice. (Pubmed Central) -  Feb 27, 2022   
    FenoNano prevented the activation of VEGF and GFAP expression and increased the AQP4 expression and the phosphorylation of PPAR-α detected by immunofluorescence compared with the diabetic mice treated with the vehicle eyedrop. Our results suggested that the fenofibrate nano-eyedrops prevent retinal glial dysfunction via the phosphorylation of PPAR-α and improves the retinal blood flow dysregulation in type 2 diabetic mice.
  • ||||||||||  glimepiride / Generic mfg.
    Trial completion:  Fenofibrate Versus Curcumin in Type 2 Diabetic Patients (clinicaltrials.gov) -  Feb 16, 2022   
    P4,  N=60, Completed, 
    Our results suggested that the fenofibrate nano-eyedrops prevent retinal glial dysfunction via the phosphorylation of PPAR-α and improves the retinal blood flow dysregulation in type 2 diabetic mice. Recruiting --> Completed
  • ||||||||||  fenofibrate nanoparticle formulation / Generic mfg., fenofibrate / Generic mfg.
    Journal:  Kinetic and Microhydrodynamic Modeling of Fenofibrate Nanosuspension Production in a Wet Stirred Media Mill. (Pubmed Central) -  Aug 11, 2021   
    A statistically significant (p-value ≤ 0.01) MLRM of three microhydrodynamic parameters explained the variation in the breakage rate constant best (R ≥ 0.99). Not only do the models and the nth-order kinetic-microhydrodynamic correlation enable deeper process understanding toward developing a WSMM process with reduced cycle time, but they also provide good predictive capability, while outperforming the purely empirical correlation.
  • ||||||||||  glimepiride / Generic mfg.
    Enrollment open:  Fenofibrate Versus Curcumin in Type 2 Diabetic Patients (clinicaltrials.gov) -  Jan 12, 2021   
    P4,  N=60, Recruiting, 
    Over 21 to 63 days, TriCor was effective in the management of primary and secondary hyperlipidemia in dogs. Not yet recruiting --> Recruiting